Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03995121 · ClinicalTrials.gov registry record
SV2 PET Imaging With [11C]APP311
A clinical trial of Healthy and Cannabis Use Disorder, sponsored by Yale University.
- Recruiting
- Registry status
- 250
- Enrollment target
- 1
- Study location
NCT03995121 is a study of Healthy and Cannabis Use Disorder that is actively recruiting participants, run by Yale University. The registered enrollment target is 250 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03995121, a study of Healthy and Cannabis Use Disorder, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to evaluate a new SV2A tracer, \[11C\]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.
Conditions Studied
Interventions
- DRUG [11C]APP311
Study Locations (1)
Connecticut
- Conneticut Mental Health Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03995121
The ClinicalTrials.gov registry entry for NCT03995121 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (61% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which [11C]APP311 is the first listed.
NCT03995121 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT03995121 about?
NCT03995121 is a clinical study titled "SV2 PET Imaging With [11C]APP311". The aim of this study is to evaluate a new SV2A tracer, \[11C\]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.
What is the current status of trial NCT03995121?
This trial is currently recruiting. The enrollment target is 250 participants. The study started on 2017-12-01. Estimated completion is 2026-12.
What conditions does trial NCT03995121 study?
This clinical trial studies the following conditions: Healthy, Cannabis Use Disorder, Schizophrenia and Other Psychotic Disorders.
What interventions are being tested in trial NCT03995121?
The interventions under investigation include: [11C]APP311 (DRUG).
Who is sponsoring clinical trial NCT03995121?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03995121 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mapping Auricular Vagus Nerve Circuitry
RECRUITING · Early Phase 1
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
The Modulatory Effect of Female Sex Hormones on Spinal Neuroplasticity
RECRUITING
-
Breathing & Blood Pressure
RECRUITING
-
Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.